Home

Methodological Issues in Clinical Drug Development for Essential Tremor

Michael A. Carranza; Madeline R. Snyder; Rodger J. Elble; Angelique E. Boutzoukas; Theresa A. Zesiewicz

Title:
Methodological Issues in Clinical Drug Development for Essential Tremor
Author(s):
Carranza, Michael A.
Snyder, Madeline R.
Elble, Rodger J.
Boutzoukas, Angelique E.
Zesiewicz, Theresa A.
Date:
Type:
Articles
Department:
Center for Parkinson's Disease and Other Movement Disorders
Volume:
2
Permanent URL:
Book/Journal Title:
Tremor and Other Hyperkinetic Movements
Abstract:
Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET.
Subject(s):
Neurosciences
Item views:
67
Metadata:
text | xml

In Partnership with the Center for Digital Research and Scholarship at Columbia University Libraries/Information Services | Terms of Use